Locations
Burlingame, CA, USA · South San Francisco, CA, USA
industry
Biotechnology · Data and Analytics · DeepTech · Information Technology · Software
Size
51-200 employees
Stage
Series B
founded in
2019
Genesis Therapeutics is leveraging an advanced molecular AI platform, GEMS, to discover and develop highly potent and selective drugs for challenging protein targets. The company focuses on using AI and physics research to synthesize drug candidates with unprecedented speed and efficacy, positioning itself as a leader in the biotech industry. With a strong emphasis on collaboration among interdisciplinary teams, Genesis aims to revolutionize drug discovery and improve patient outcomes. Their recent strategic collaborations and significant funding rounds highlight their traction and market position in the competitive landscape of drug development.
Something looks off?On-site & Remote